Singapore’s Dx Assay Pushing Fee-for-service Model In Companion Diagnostics
This article was originally published in PharmAsia News
Dx assays Pte. Ltd. says its fee-for-service business model makes it a unique provider of companion diagnostics in a market set to boom globally as U.S. FDA and other regulators push for drug firms to develop diagnostics alongside drugs.
You may also be interested in...
FDA released long-awaited draft guidance on the development of drugs with companion diagnostics July 12, but the 12-page document’s concise nature left some in the industry longing for more insight.
SINGAPORE - The Singaporean government's leading investments arm, EDB Investments, is increasingly betting on small-sized companies that leverage advanced communication technologies like mobile phones or remote monitoring to develop healthcare solutions
PERTH, Australia - Dx Assays, Singapore's first commercial developer of molecular diagnostic assays, opened its new R&D center in Singapore Sept. 8